Peterson, P K, Pheley, A, Schroeppel, J et al. · Archives of internal medicine · 1998 · DOI
This study tested whether a low-dose steroid medication called fludrocortisone could help ME/CFS patients feel better. Twenty participants took either the medication or a placebo for 6 weeks each, in random order. The medication did not improve fatigue, other symptoms, or physical function compared to placebo, and it did not cause more side effects than placebo.
This negative trial helps clarify which potential treatments do not have broad utility in ME/CFS, preventing patients from pursuing ineffective therapies and directing research toward more promising avenues. It also demonstrates the value of rigorous placebo-controlled testing in a condition where symptom heterogeneity and placebo response rates are substantial.
This study does not prove that fludrocortisone is ineffective in all ME/CFS patients or in every subtype of the disease; it may have benefit for carefully selected subgroups not examined here (e.g., patients with documented orthostatic intolerance or norepinephrine dysregulation). A negative preliminary trial with a small sample does not exclude the possibility of benefit at different doses or in patients with specific biomarker profiles.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →